At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Closed 02-04 16:00:00 EST
6.08
-0.48
-7.32%
盘后6.07
-0.01-0.15%
19:54 EST
High6.67Low5.95Vol929.60K
Open6.61D1 Closing6.56Amplitude11.05%
Mkt Cap197.73MTradable Cap137.57MTotal Shares32.52M
T/O5.69MT/O Rate4.11%Tradable Shares22.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Dow Jones  ·  02-04 04:27
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded
Deep News  ·  02-03 22:54
Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-03 20:39
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Sagimet Biosciences initiated with a Buy at Guggenheim
TIPRANKS  ·  02-03 20:21
Sagimet Biosciences initiated with a Buy at Guggenheim
Sagimet Biosciences price target raised to $37 from $29 at Clear Street
TIPRANKS  ·  02-03 18:20
Sagimet Biosciences price target raised to $37 from $29 at Clear Street
Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)
TIPRANKS  ·  02-03 15:51
Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)
BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
Reuters  ·  02-02 20:24
BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
Sagimet Biosciences announces license partner Ascletis issues results for ASC40
TIPRANKS  ·  02-02 20:21
Sagimet Biosciences announces license partner Ascletis issues results for ASC40
Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne
Reuters  ·  02-02 20:00
Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne
Sagimet Announces Positive 52-Week Data From License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of Asc40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne
THOMSON REUTERS  ·  02-02 20:00
Sagimet Announces Positive 52-Week Data From License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of Asc40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne
Sagimet Biosciences Inc - Denifanstat Well Tolerated With Teaes Incidence Rate of 5% or More
THOMSON REUTERS  ·  02-02 20:00
Sagimet Biosciences Inc - Denifanstat Well Tolerated With Teaes Incidence Rate of 5% or More
Sagimet Biosciences Inc - Denifanstat Shows Improvements in Efficacy Endpoints Beyond 12 Weeks
THOMSON REUTERS  ·  02-02 20:00
Sagimet Biosciences Inc - Denifanstat Shows Improvements in Efficacy Endpoints Beyond 12 Weeks
Multiple Shots on Goal: Sagimet’s Differentiated MASH Combo and Acne Franchise Underpin Buy Rating and Favorable Risk‑Reward
TIPRANKS  ·  02-02
Multiple Shots on Goal: Sagimet’s Differentiated MASH Combo and Acne Franchise Underpin Buy Rating and Favorable Risk‑Reward
Ascletis Pharma New Drug Application for Denifanstat Accepted by China National Medical Products Administration
Reuters  ·  01-29
Ascletis Pharma New Drug Application for Denifanstat Accepted by China National Medical Products Administration
Sagimet Biosciences Initiated at Equal-Weight by Barclays
Dow Jones  ·  01-28
Sagimet Biosciences Initiated at Equal-Weight by Barclays
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target
MT Newswires Live  ·  01-28
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target
TIPRANKS  ·  01-10
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
GlobeNewswire  ·  01-08
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH
Reuters  ·  2025-12-18
Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH
Sagimet Biosciences Inc - Plans Phase 2 Trial for Mash With F4 Fibrosis
THOMSON REUTERS  ·  2025-12-18
Sagimet Biosciences Inc - Plans Phase 2 Trial for Mash With F4 Fibrosis

Introduction

Company Name.
Sagimet Biosciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Issue price:
--